munocompromised status of the patient but also metabolic derangements, including lipoprotein disorders that may lead to cardiovascular disease [1] . One of these problems is increased oxidative stress resulting from either the infection itself or the secondary effects of treatments [2] . Paraoxonase-1 (PON1) is an enzyme with antioxidant properties. PON1 is an esterase and lactonase that catalyzes the hydrolysis of oxidized phospholipids and lipophylic lactones [3] . In the general population and in patients with diabetes, PON1 preserves high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs) from peroxidation and, as such, has been associated with a protective role against the development of atherosclerosis [4] [5] [6] [7] [8] . PON1 knockout mice have increased macrophage oxidative stress and are more susceptible to atherosclerosis than are other mice [9] , and human PON1 transgenic mice have decreased atherosclerosis formation and lipoprotein oxidation [10] . PON1 attenuates in vitro production of monocyte chemoattractant protein-1 (MCP-1) by monocytes. MCP-1 is a proinflammatory chemokine that is involved in the initial step of formation of the atheromatous plaque [11] . Previous studies from our group demonstrated an increased plasma MCP-1 concentration in HIV-infected patients and an association between the polymorphisms in the MCP-1 Ϫ2518 allele and the presence of subclinical atherosclerosis [12] . We have also reported elsewhere [13] that PON1 status is influenced by the course of HIV infection and results in a decrease in PON1 activity. The hypothesis of the present study is that the relationship between oxidative stress, HIV infection, and atherosclerosis is such that PON1 gene polymorphisms could be associated with the metabolic disturbances associated with the infection, as well as with the immunologic, virologic, and clinical course of this disease.
METHODS

Study population and design.
In an initial study, we performed case-control comparisons to assess the differences in genotype distributions of the PON1 genes in HIV-infected patients, compared with differences in the PON1 gene distributions noted in the general population. The study participants who were used as the control group enrolled in a populationbased study conducted in our area. Details of this study have been published elsewhere [14] . In brief, the 633 participants Expanding on the initial study, we performed a case-control assessment of the HIV-infected patients receiving antiretroviral treatment. The purpose of the assessment was to evaluate any associations of PON1 gene haplotypes with the metabolic, immunologic, and virologic variables measured. In this second study, we defined as "cases" those HIV-infected patients who had lipodystrophy, metabolic disturbances, dyslipidemia (as defined by the National Cholesterol Education Program Adult Treatment Panel III as a total cholesterol level 15.0 mmol/L or an LDL cholesterol level 13 .0 mmol/L; an HDL cholesterol !1.0 mmol/L in men and !1.2 in women; or a triglyceride level 11.7 mmol/L), a positive cardiovascular disease risk (as assessed by the Framingham risk score), and the presence of atherosclerosis, as determined by measurement of the intima-media thickness (IMT) in the carotid artery. Although IMT is a continuous variable, and although we have reported the data in this form, we also defined subclinical atherosclerosis as (1) a categorical (dichotomized) variable when the IMT was 10.8 mm or (2) the presence of an atheromatous plaque in the analyzed zones of the arteries.
We used previously established definitions of cases and controls in association with the magnitude of the increase in the CD4 + cell count-that is, we reassigned the HIV-infected patients as cases or controls on the basis of their response or lack of response, respectively, to anti-HIV treatment. Patients who did not have a CD4
+ cell count increase of 150 cells/mm 3 after 12 months of treatment follow-up were considered to be "nonresponders" [15] . In terms of virologic variables, we considered cases to be those patients who experienced a rebound in the viral load during the course of the 12-month observational period of the study. Patients who abandoned treatment and those who completed the 12-month observational period with a negative viral load were censored from the present statistical analyses.
All the participants provided fully informed consent. The data were coded to ensure anonymity. The study was approved by the ethics committee of the Hospital Universitari de Sant Joan de Reus. All procedures were performed according to the principles of the Declaration of Helsinki and Good Clinical Practice.
Biochemical measurements. A sample of fasting venous blood was obtained during the clinical examination. The plasma viral load was measured using the Cobas TaqMan HIV-1 assay (Roche), and the CD4 + T cell count was determined using flow cytometry (Beckman-Coulter). HDL cholesterol levels were analyzed by a homogeneous method (Beckman-Coulter). LDL cholesterol levels were calculated using the Friedewald formula [16] . Serum total cholesterol and triglyceride concentrations were measured by standard methods (Beckman-Coulter). Serum PON1 esterase activity was measured as the rate of hydrolysis of paraoxon at 410 nm and 37ЊC in 0.05 mmol/L glycine buffer (pH 10.5) with 1 mmol/L calcium chloride [17] . Activities were expressed as the number of units per liter, where 1 unit equals 1 micromole of paraoxon hydrolyzed per minute. Serum PON1 lactonase activity was measured in an assay reagent containing 1 mmol/L calcium chloride, 0.25 mmol/L 5-(thiobutyl)-butyrolactone (TBBL), and 0.5 mmol/L 5,5 -dithiobis-2-nitrobenzoic acid (DTNB) in 0.05 mmol/L Tris-HCL buffer (pH 8.0). The increase in absorbance was monitored at 412 nm [18, 19] . Activities were expressed as the number of units per liter, where 1 unit equals 1 millimole of TBBL hydrolyzed per minute. The serum PON1 concentration was de- termined by enzyme-linked immunosorbent assay (ELISA) performed using an antibody raised against a peptide derived from the sequence of mature PON1 [6] . The serum concentration of oxidized LDL was measured by ELISA (Mercodia). Serum apolipoprotein (apo) A-I and A-II concentrations were determined by immunoturbidimetry (Beckman-Coulter and Dialab Gmbh, respectively). The serum concentration of C-reactive protein (CRP) was measured using a high-sensitivity method (Beckman-Coulter). The plasma concentration of MCP-1 was measured by ELISA (Human MCP-1 ELISA Development Kit; Prepotech).
Genotyping. Genomic DNA was obtained from leukocytes (Puregene DNA Isolation reagent set; Gentra Systems). PON1 192 , PON1 55 , PON1 Ϫ162 , PON1 Ϫ832 , PON1 Ϫ909 , PON1 Ϫ1076 , PON1 Ϫ1741 , and MCP-1 Ϫ2518 single-nucleotide polymorphisms (SNPs) were analyzed using the Iplex Gold MassArray method (Sequenom) at the Spanish National Genotyping Center (Centro Nacional de Genotipado of the Universitat Pompeu Fabra, Barcelona, Spain).
Arterial IMT measurement. We performed carotid and femoral ultrasound measurements for 183 HIV-infected patients. By use of an identical protocol, these measurements were conducted by the same investigators who performed a previously published study [12] , all of whom were blinded with respect to the results of the other variables studied. We used a GE Logiq 700 with an ultrasound probe of 7-10 MHz. We identified 3 segments in the carotid arteries on which to conduct the measurements: the common carotid artery (1 cm proximal to the bifurcation), the carotid bulb (in the bifurcation), and the internal carotid artery (1 cm distal to the bifurcation). We evaluated the common femoral artery 1 cm proximal to the bifurcation. The far-wall IMT images were obtained and digitized for each participant.
Statistical analysis. We used the test to assess the degree 2 x of association between categorical variables. An analysis of variance (ANOVA) test or Student's t test was used for continuous variables that followed a normal distribution. The Mann-Whitney U test and the Wilcoxon rank-sum test were used for nonparametric variables. The results are presented as the mean value ‫ע‬ standard deviation (SD), for parametric variables, and the median value (range), for nonparametric variables. SNPs were tested for Hardy-Weinberg equilibrium by use of Haploview software (version 4.0; Broad Institute) [20] . Estimates of linkage disequilibrium between SNPs were calculated using D and . Haplotype estimations were performed using PHASE 2 r software (version 2; University of Chicago) [21] with default settings and the SNPator package (CeGen) [22] . Linear or logistic regression models were used to identify the haplotypes that predicted the dependent variables after adjustment for potential confounding factors, such as age, sex, dyslipidemia, smoking habit, hypertension, fasting glucose, body mass index, hepatitis C virus coinfection, lipid-lowering treatment, duration of each antiretroviral treatment scheme, and basal CD4 + cell count. The Kaplan-Meier hazard model was used to determine the association between the haplotypes and the time to an undetectable viral load at a 95% confidence interval (CI). All statistical analyses were performed using the SPSS statistical package (version 15.0; SPSS). 
RESULTS
Genotype distributions in control subjects and HIV-infected patients. The general characteristics of the patients are summarized in Table 1 ) be-P p .001 tween control subjects and HIV-infected patients (Figure 2A) .
Association of PON1 haplotypes with the immunologic and virologic outcomes in HIV-infected patients. In a bivariate analysis, we found significant differences in the CD4 + cell counts of HIV-infected patients segregated according to haplotype. Patients carrying the H7 haplotype had higher basal CD4 + cell counts ( Figure 2B and Table 3 ). After segregating patients according to CD4
+ cell count, we also observed a greater number of responders among patients carrying the H7 haplotype than among patients who did not carry this haplotype (72.9% vs 52.7%;
). P p .017 The probability of maintaining an undetectable viral load while receiving antiretroviral treatment was also significantly associated with PON1 gene haplotypes. Carrying haplotypes H10 and H5 was associated with a higher probability of maintaining viral suppression ( and , respectively). P p .047 P p .022 Association of PON1 haplotypes with the presence of lipodystrophy, metabolic disturbances, cardiovascular disease risk, and dyslipidemia. We did not observe (by use of bivariate analysis) any association between PON1 haplotypes and lipodystrophy, metabolic disturbances, or the 10-year risk of cardiovascular disease, as assessed by the Framingham risk score. However, we did find an association between dyslipidemia and the H7 and H4 haplotypes ( and , respec-P p .025 P p .006 tively). Patients carrying the H7 haplotype had lower serum triglyceride concentrations, higher HDL cholesterol levels, and higher apo A-I and apo A-II concentrations (Table 3) .
HIV-infected patients carrying the H4 haplotype also had lower serum triglyceride levels (mean ‫ע‬ SD, 2. P p .028 Association of PON1 haplotypes with the presence of subclinical atherosclerosis in HIV-infected patients. We found an association between the presence of subclinical atherosclerosis and the H7 haplotype ( Figure 2C ). Patients who did not carry this haplotype had higher rates of subclinical atherosclerosis (83.3% vs 16.7%;
). In the logistic regression model, P ! .001 ). P p .026 We did not observe any significant association between the serum PON1 activity or concentration and the immunologic, virologic, metabolic, or clinical variables analyzed.
DISCUSSION
The results of the present study show significant differences between control subjects and HIV-infected patients with respect to the genetic distribution of 2 PON1 gene haplotypes. The H10 haplotype is more prevalent in HIV-infected patients than in control subjects, although the small number of participants carrying this haplotype makes this conclusion very preliminary. The absence of the H10 haplotype is also associated with a higher probability of maintaining a negative viral load. As such, we can suggest that this haplotype is more prevalent in HIVinfected patients because it is associated with increased patient survival. The H5 haplotype is significantly less prevalent in HIVinfected patients than in control subjects, and its absence is also associated with a higher probability of maintaining viral suppression. Perhaps patients with this genotypic background show less capability of controlling viral replication when receiving antiretroviral treatment and may be less protected in the first stages of HIV transmission.
The strong linkage disequilibrium observed between the SNPs of PON1 also allowed us to detect candidate SNPs with functional and clinical implications that warrant further investigation. PON1 192 codes for isoenzymes that show different functional antioxidant activity, as has been reported elsewhere [5, 23] . The H10 and H5 haplotypes contain the R allele at position 192; the R allele is the allele that is least effective in protection against lipid peroxidation [7] . The H7 haplotype appears to have an important role with respect to the lipid profile, the presence of atherosclerosis, and the CD4 + cell count. We observed that patients who carried this haplotype had higher levels of HDL cholesterol and apo A-I, as well as lower triglyceride levels. The H7 haplotype was also associated with lower rates of subclinical atherosclerosis. In the multivariate regression model, the absence of the haplotype predicted the presence of atherosclerosis, after adjustment for other classical cardiovascular disease risk factors. Also in the regression model, the adjusted apo A-I levels, but not the triglyceride levels, were predicted by the H7 haplotype. That apo A-I and HDL levels are influenced by the PON1 polymorphisms can be hypothesized to be an effect related to conformational changes in the PON1 isoform, which confers a more stable binding to apo A-I [24] . The H7 haplotype carries the Q allele at the PON1 192 position, and this allele is known to confer better antioxidant properties and better protection against the development of atherosclerosis, compared with other alleles [5] .
It is of note that the H7 haplotype was also associated with higher basal CD4 + cell counts and better CD4 + cell recovery with treatment. The basal CD4 + cell count is an independent risk factor for atherosclerosis in HIV-infected patients [25, 26] . As such, it is possible that the PON1 genotypic background modulates the lipid profile and also confers a better oxidative status, which, in turn, lowers CD4 + cell apoptosis and, consequently, lowers the predisposition to atherosclerosis related to the proinflammatory and prooxidative status of this patient population.
A caveat of the present study is that, despite a clear association between PON1 gene haplotypes and severe complications of HIV infection, we did not observe any significant association between these derangements and circulating levels of PON1, with respect to either the activity or the concentration of the enzyme. The explanation for this phenomenon cannot be ascertained from the present study, but a possible underlying mechanism could be related to the aforementioned observation-that is, the PON1 192 polymorphism may influence PON1 binding to apo A-I and HDL, causing differences in enzyme stability and modifying HDL function independently of PON1 levels [24] . Our results showing that patients who carry the H7 haplotype (which contains the PON1 192 polymorphism) have higher HDL cholesterol and apo A-I concentrations would tend to support this hypothesis. Another limitation of the present study is its cross-sectional design, which makes any conclusions about associations with disease progression and pathogenesis very preliminary. Prospective, longitudinal studies investigating the influence of PON1 haplotypes on seroconversion and patient survival would be necessary to describe more clearly the role of these haplotypes in disease progression.
In conclusion, PON1 haplotypes are associated with HDL and apo A1 levels, the presence of atherosclerosis, immunologic status, and virologic outcome after treatment. The clinical implication is that novel therapeutic strategies may need to take into account the PON1 genotypic background of the patient, especially if the therapeutic option is to modulate serum PON1 activity and HDL or apoA-I levels [27, 28] . Our results suggest that the PON1-HDL complex may play a role in the homeostasis of atherosclerosis and HIV infection (ie, the HDL part of the complex is involved in reverse cholesterol transport and catabolism, whereas the PON1 part modulates inflammation, oxidative status, and the immunologic system). This concept warrants further research, because it is an aspect that may provide beneficial consequences for these patients for whom effective treatment options with less toxic effects currently are not very extensive.
